Prothena (PRTA)
(Delayed Data from NSDQ)
$16.86 USD
+0.06 (0.36%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $16.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.86 USD
+0.06 (0.36%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $16.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.
Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More
by Kinjel Shah
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
by Zacks Equity Research
Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.
Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows
Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar?
by Zacks Equity Research
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Is Prothena (PRTA) Up 46.8% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.
Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 7.23% and 80.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Prothena (PRTA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Prothena (PRTA) Down 19.9% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -13.24% and -70.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II
by Zacks Equity Research
Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.
Prothena (PRTA) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session
by Zacks Equity Research
Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 1.67% and -37.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.
Options Traders Expect Huge Moves in Prothena (PRTA) Stock
by Zacks Equity Research
Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.
Why Is Prothena (PRTA) Up 36.1% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3
by Zacks Equity Research
Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.